Meds A-Z
Nitenpyram
Detailed information about Nitenpyram
Pet Owner Quick Guide
Start here: what this medicine is for, what it does, and when it's usually needed.
Usually used for:
For the treatment of flea infestations.
What it does:
For the treatment of flea infestations. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets is indicated to kill adult fleas and prevent flea eggs from hatching. In cats and kitt...
When it's needed:
For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order...
Call your vet sooner if you notice:
- For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian. For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian.
Commonly reported reactions:
- (2 reports)
- (2 reports)
- (2 reports)
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Nitenpyram
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: MSK
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141175 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141204 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian. For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian.
- High: For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian. For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian.
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Most Reported Reactions
| Reaction | Cases | Species | Serious cases |
|---|---|---|---|
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 1 | |
| 2 | Cat, Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Cat | 1 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Cat | 1 |
Species coverage: Cat (17) Dog (15)
View detailed reaction table
| Reaction | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-054642
Storage & Handling
No storage/handling guidance is linked yet.
Documents
Official label facts are separated from secondary summaries.
Official documents: 7 • Secondary summaries: 0
- ucm117260.pdf · FOI
- ucm117258.pdf · FOI
- CAPSTAR® · SPL
- ucm117654.pdf · FOI
- Sentinel® Flavor Tabs® and Capstar® Flea Management System™ · SPL
- ucm117656.pdf · FOI
- Program® Flavor Tabs® and Capstar® Flea Management System™ · SPL
No source yet.
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/685 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/684 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/487/CAPSTAR%C2%AE · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/722 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/291/Sentinel%C2%AE%20Flavor%20Tabs%C2%AE%20and%20Capstar%C2%AE%20Flea%20Management%20System%E2%84%A2 · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/723 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/443/Program%C2%AE%20Flavor%20Tabs%C2%AE%20and%20Capstar%C2%AE%20Flea%20Management%20System%E2%84%A2 · document · SPL
Promotional Materials (Marketing)
This content is marketing material and not clinical guidance.
No marketing assets are linked yet.
No source yet.
Technical appendix (vet reference)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:02 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
- For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian. For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian. (Contraindication, High)
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 21091-141-01 | 21091 | - | |
| 21091-141-05 | 21091 | - | |
| 21091-142-01 | 21091 | - | |
| 21091-142-05 | 21091 | - | |
| 21091-175-01 | 21091 | - | |
| 21091-175-03 | 21091 | - | |
| 21091-175-04 | 21091 | - | |
| 21091-175-05 | 21091 | - | |
| 21091-178-01 | 21091 | - | |
| 21091-178-03 | 21091 | - | |
| 21091-178-04 | 21091 | - | |
| 21091-178-05 | 21091 | - | |
| 62157-725-01 | 62157 | - | |
| 73309-146-01 | 73309 | - | |
| 73309-146-02 | 73309 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
ucm117258.pdf
• FOI summary • Official
• May 17, 2021
FDA FOI summary for application 141175
-
ucm117260.pdf
• FOI summary • Official
• May 17, 2021
FDA FOI summary for application 141175
-
ucm117654.pdf
• FOI summary • Official
• Aug. 3, 2020
FDA FOI summary for application 141204
-
ucm117656.pdf
• FOI summary • Official
• June 1, 2016
FDA FOI summary for application 141205
Data Sources & Revision History
Every non-trivial field is expected to include provenance and update timestamps.
- contraindications: For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavo… (Official, 2026-02-12)
- side_effects: Top reported reactions (openFDA): Lack of efficacy (ectoparasite) - flea, Lack of efficacy (flea), Vomiting, Lethargy (see also Central nervous system depressi… (Official, 2026-02-12)
- usage: For the treatment of flea infestations. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets is indicated to kill adul… (Official, 2026-02-12)
- side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
CAPSTAR®
OTC
Nitenpyram
Tablet
• Oral
|
Sergeant’s Pet Care Products LLC | NADA 141-175 | Approved | May 17, 2021 |
|
Sentinel® Flavor Tabs® and Capstar® Flea Management System™
RX
Lufenuron Milbemycin Oxime Nitenpyram
Tablet
• Oral
|
Intervet, Inc. | NADA 141-204 | Approved | Aug 3, 2020 |
|
Program® Flavor Tabs® and Capstar® Flea Management System™
RX
Lufenuron Nitenpyram
Tablet
• Oral
|
Elanco US Inc. | NADA 141-205 | Approved | Jun 1, 2016 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
concurrent with
Tablet contains 11.4 or 57 milligrams nitenpyram.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
CAPSTAR® Tablets: 11.4 mg and 57 mg nitenpyram
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
-
FOI ucm117260.pdf
Summary
1. The text in the “Indications” section is changed to include the words “kill adult fleas.” The section will now read: “CAPSTAR® Tablets kill adult fleas and are indicated for the treatment of flea infestations on dogs, puppies, cats and kittens 4 weeks of age and older and 2 pounds of body weight or greater.” This change makes the labeling more consistent with labeling for other approved products that kill adult fleas.
2. There are some minor revisions to clarify the currently approved text in the package insert and the unit dose cartons.
3. The package insert is revised to include reference to the concurrent use of PROGRAM® (lufenuron) Flavor Tabs® (NADA 141-035) to kill adult fleas and prevent flea eggs from hatching. The information supporting approval for this concurrent use is documented in NADA 141-205.
4. The package insert is revised to refer the reader to a veterinarian for information about the concurrent use of SENTINEL® (milbemycin oxime/lufenuron) Flavor Tabs® (NADA 141-084), to kill adult fleas and prevent flea eggs from hatching. SENTINEL® Flavor Tabs® are a prescription product. The information supporting approval for this concurrent use is documented in NADA 141-204.
5. The unit dose cartons are revised to refer to concurrent use with PROGRAM® (lufenuron) Flavor Tabs®.
6. Each unit dose carton will contain an additional “FLEA MANAGEMENT SYSTEM” package insert that provides specific information for using CAPSTAR® Tablets with PROGRAM® (lufenuron) Flavor Tabs®. -
FOI ucm117258.pdf
Summary
For the treatment of flea infestations on dogs, puppies, cats and kittens four weeks of age and 2 pounds of body weight or greater.
- CAPSTAR® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI ucm117654.pdf
Summary
For use in dogs 4 weeks and older to kill adult fleas and to prevent flea eggs from hatching.
FDA page: Open in Animal Drugs @ FDA
-
FOI ucm117656.pdf
Summary
For use to kill adult fleas and to prevent flea eggs from hatching.
FDA page: Open in Animal Drugs @ FDA
Usage
For the treatment of flea infestations. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets is indicated to kill adult fleas and prevent flea eggs from hatching. In cats and kittens, the concurrent use of PROGRAM® Flavor Tabs® and CAPSTAR® Tablets is indicated to kill adult fleas and prevent flea eggs from hatching. The effects of PROGRAM® Flavor Tabs®, which control flea populations, and CAP STAR® Tablets, which treat flea infestations, are combined to provide a FLEA MANAGEMENT SYSTEM™.
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
For use in dogs, puppies, cats, and kittens 4 weeks of age and older and 2 pounds of body weight or greater. The concurrent use of nitenpyram tablets and flavored milbemycin/lufenuron tablets shall be by or on the order of a licensed veterinarian. For use in cats and kittens 4 weeks of age and older. The concurrent use of flavored milbemycin oxime and lufenuron tablets with nitenpyram tablets shall be by or on the order of a licensed veterinarian.
Side Effects
No approved side-effect narrative is linked yet.
openFDA reaction signals are available for Dog 56 and Cat 56 (view top reported reactions).
Top Reported Reactions (openFDA)
Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Cat, Domestic Shorthair, Male, 6 month, 4.082 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per year • Reactions: Panting, Increased heart rate, Anxiety, Fever • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-055702
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 6.00 Month
- Weight: 4.082 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 1 tablet per dose
- Frequency: 1 per year
Cat, Domestic Shorthair, Female, 8 year, 3.629 kilogram • Drug: MSK, Tablet, Oral, Dose: 11.40 Milligram per dose, Frequency: 1 per year • Reactions: Oral bleeding, Haemorrhage NOS, Food refusal, Cardiac arrest, Death… • Outcome: Died
- Report ID: USA-USFDACVM-2025-US-055214
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Female
- Age: 8.00 Year
- Weight: 3.629 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 11.40 Milligram per dose
- Frequency: 1 per year
Cat, Domestic Longhair, Female, 15 year, 3.175 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per year • Reactions: Found dead • Outcome: Died
- Report ID: USA-USFDACVM-2025-US-055212
- Serious AE: Yes
- Treated For AE: No
- Sex: Female
- Age: 15.00 Year
- Weight: 3.175 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 1 tablet per dose
- Frequency: 1 per year
Dog, Dachshund (unspecified), Female, 9 year, 7.711 kilogram • Drug: MSK, Tablet, Oral, Dose: 11.40 Milligram per dose, Frequency: 1 per day • Reactions: Tremors, Tiredness (lethargy), Panting, Twitching, Systemic disorder NOS • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-055213
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Female
- Age: 9.00 Year
- Weight: 7.711 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 11.40 Milligram per dose
- Frequency: 1 per day
Cat, Domestic Longhair, Male, 3 year, 5.443 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per day • Reactions: Tiredness (lethargy), Appetite loss, Blood in vomit, Not drinking, Vomiting… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-054642
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 3.00 Year
- Weight: 5.443 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 1 tablet per dose
- Frequency: 1 per day
Dog, Shar Pei, Male, 8 month, 18.144 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per year • Reactions: Vomiting, Diarrhea, Decreased drinking, Not eating, Other abnormal test result NOS… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-054640
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 8.00 Month
- Weight: 18.144 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 1 tablet per dose
- Frequency: 1 per year
Cat, Russian, Male, 4 year, 6.804 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per day • Reactions: Vocalisation, Biting - pruritus, Fever, Hyperactivity, Tiredness (lethargy)… • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-055701
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 4.00 Year
- Weight: 6.804 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 1 tablet per dose
- Frequency: 1 per day
Dog, Griffon - Brussels, Male, 5 year, 3.629 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per dose, Frequency: 1 per day • Reactions: Tiredness (lethargy), Dazed, Hiding, Gait abnormality, Vocalisation… • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-053769
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 5.00 Year
- Weight: 3.629 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 1 tablet per dose
- Frequency: 1 per day
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.